Mosunetuzumab in Patients With Relapsed/Refractory DLBCL Treated With ≥2 Prior Lines of Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Blood Adv 2023 Apr 17;[EPub Ahead of Print], NL Bartlett, S Assouline, P Giri, SJ Schuster, CYY Cheah, MJ Matasar, GP Gregory, DH Yoon, M Shadman, K Fay, SS Yoon, C Panizo, IW Flinn, A Johnston, F Bosch, LH Sehn, MC Wei, S Yin, I To, CC Li, H Huang, A Kwan, E Penuel, EE BuddeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.